The PROactive study found that Takeda's ACTOS (pioglitazone HCl) significantly reduced the combined risk of non-fatal heart attacks, strokes, and deaths by 16% in high-risk patients with type-2 diabetes. This led to a 10% reduction in the primary combination endpoint of seven different macrovascular events.
The PROactive study shows that ACTOS significantly improves cardiovascular outcomes by reducing heart attacks, strokes, and death in high-risk patients. The study found a 16% reduction in life-threatening events and significant improvements in lipid profiles, blood pressure, and insulin resistance.
Studies show that FUZEON combined with tipranavir achieves a ten-fold reduction in viral load and double the increase in immune cell count. The 'FUZEON effect' has been seen across multiple studies, nearly doubling patients reaching undetectable viral loads.
Takeda has submitted a new drug application for its combination type 2 diabetes medication, ACTOS (pioglitazone HCl) and glimepiride. This treatment aims to help patients manage their blood glucose levels by targeting insulin resistance and increasing insulin production.
A new study shows that ACTOS significantly improved components of diabetic dyslipidemia compared to Avandia. The results indicate that treatment with ACTOS lowered triglycerides and increased HDL-C, while improving LDL-C particle concentration and size. This is important for reducing cardiovascular risk in patients with type 2 diabetes.
A new study found that ramelteon helped adults with chronic insomnia fall asleep faster and sleep longer, while also demonstrating no abuse potential or behavioral impairment. Ramelteon works by targeting two brain receptors, MT1 and MT2, to regulate the body's circadian rhythms.
A study found that ACTOS reduced inflammation markers CRP and IL-6, improving glycemic control in patients with stable blood sugar levels. Treatment with ACTOS resulted in significant decreases in these markers compared to placebo.
A new study demonstrated add-on effects of ACTOS on diabetic dyslipidemia, reducing triglycerides and increasing HDL cholesterol. Patients with type 2 diabetes who switched from Avandia to ACTOS showed significant improvements in lipid levels, regardless of age or gender.
A study shows that ramelteon effectively reduces insomnia symptoms in elderly individuals, targeting the suprachiasmatic nucleus to regulate biological rhythms. Approximately half of older adults experience insomnia at least a few nights per week, affecting an estimated 60 million people in the US.
CellCept shows benefits for liver transplant patients, similar to those seen in kidney transplant recipients, with reduced risk of acute rejection and improved kidney function. The treatment also promotes safe steroid-free regimens and reduces liver fibrosis.
A new study assesses the feasibility and effectiveness of personalized immunosuppression using CellCept, a leading immunosuppressant in kidney transplantation. The study found that tailored dosing strategies can minimize toxicity while maximizing efficacy, offering improved patient care.
A steroid-free regimen with CellCept was found to be comparable to standard therapy in liver transplantation, without increasing the risk of hepatitis C recurrence. The study involved 312 adult patients and showed that the CellCept-based regimen demonstrated comparable efficacy and safety profiles.
A study found that ramelteon demonstrated no abuse potential, unlike triazolam, with no dose-related effect on task performance. Ramelteon targets the MT1 and MT2 receptors in the brain's suprachiasmatic nuclei, providing a new mechanism of action for insomnia treatment.
A randomized study of 829 older adults found that ramelteon significantly reduced time to fall asleep and showed no rebound insomnia. Ramelteon targets the brain's suprachiasmatic nuclei (SCN) and has a new mechanism of action, providing an alternative treatment option for insomnia.
The American Urological Association has awarded Novartis Pharmaceuticals its annual health science award in recognition of the company's support for the organization's educational, scientific, and research goals. The award acknowledges Novartis' contributions to promoting urologic care through continuing medical education.
Researchers found that freedom from rejection after 12 months was 10% higher with those treated with CellCept (63%) compared to azathioprine (53%). Additionally, the one-year survival rate was significantly better in CellCept patients (96%), compared to only 87% of AZA patients.
A large-scale study of 39,462 members found that electronic medical records can reduce hospitalizations by 19% and annual paid claims by $817. The CareEngine system improved patient outcomes while reducing costs, highlighting the potential of clinical decision support tools.
EMSELEX, a new drug for treating overactive bladder, has shown efficacy in reducing incontinence episodes by up to 77% compared to placebo. The medication, selective for the M3 receptor, also improves symptoms such as urinary frequency and urgency.
A new study examined ACTOS and Avandia's lipid-altering effects in patients with type 2 diabetes. The results suggest looking beyond glycemic effects to potential lipid benefits, which could inform treatment strategies.
Researchers found that pioglitazone significantly reduced carotid artery thickness in just 12-24 weeks, while improving insulin resistance. This regression was independent from metabolic control improvements and correlated with better cardiovascular outcomes for patients with type 2 diabetes.
A new analysis of the CHARM* study program shows that Atacand reduces all-cause mortality by 12% and cardiovascular mortality by 16%. The medication is recommended for all patients with heart failure and low LVEF, regardless of background treatment.
Emselex(R) has been proven to improve overactive bladder (OAB) symptoms without causing significant adverse events. The treatment has shown efficacy in reducing urinary urgency and urge incontinence, making it a promising new option for patients.
FUZEON shows significant benefits in health improvements and reduced side effects for HIV patients, yet many are missing out due to fear of injection. Physicians and nurses play a pivotal role in educating patients on optimal use of FUZEON.
The PROactive study assesses the effect of ACTOS on cardiovascular disease progression in patients with type 2 diabetes. The study examines whether pioglitazone reduces cardiovascular mortality and morbidity in a high-risk population.
Darifenacin significantly improves quality of life for people with overactive bladder (OAB) symptoms, enabling them to undertake household tasks, socialise, work, and travel. The medication reduces the number of weekly incontinence episodes by up to 77% and shows comparable CNS and CV safety to placebo.
The European Commission has approved the combination of Herceptin and Taxotere as a first-line treatment for HER2-positive breast cancer, significantly improving median life expectancy by over one-third. The therapy also showed high response rates, with 61% of patients responding to treatment.
A long-term study published in JADA demonstrates that rinsing twice daily with Listerine Antiseptic mouthrinse is as effective at reducing plaque and gingivitis as flossing once daily. The study found that Listerine Antiseptic reduced plaque by 20% and gingivitis by 11%, while flossing led to 3.4% and 4.3% reductions respectively.
A study of 3,140 patients found pioglitazone to lower blood pressure in both Stage I and Stage II hypertension cases. This effect could reduce cardiovascular disease risk factors in patients with type 2 diabetes.
ACTOS therapy has favorable effects on dyslipidemia, including reductions in triglycerides and increases in HDL cholesterol. Additionally, ACTOS was found to have beneficial effects on non-HDL cholesterol and A1C levels.
Studies presented at the American Diabetes Association annual meeting showed ACTOS to be effective in reducing fasting insulin levels and improving A1C levels, with significant benefits seen when used alone or in combination with other oral antidiabetic medications.
A landmark UK study sponsored by Diabetes UK, Department of Health, and Pfizer UK showed that 10mg atorvastatin reduced cardiovascular events by 37% in patients with diabetes without existing CVD. Stroke was substantially reduced by 48% in these patients.
Studies of over 61,000 transplant patients demonstrate CellCept's unique survival benefits for solid organ transplant recipients. Additionally, CellCept reduces acute rejection rates and improves graft function, while also providing a lower risk of infectious death.
A new study found that a single daily dose of Valcyte is equally effective as three times daily Cytovene in preventing CMV in kidney transplant patients. This simplified regimen may improve care and quality of life for transplant recipients by reducing medication complexity.
The study showed that ganciclovir treatment lowers the risk of developing cancer and early organ rejection in kidney transplant patients. Ganciclovir offers dual benefits, extending patient life by reducing malignancy and improving graft survival with reduced rejection.
A Phase III maintenance trial of natalizumab found sustained clinical response and remission rates among patients with Crohn's disease. The study also showed that a majority of patients on corticosteroids were able to withdraw from the medication without losing their response.
Data from over 35,000 organ recipients demonstrated improved patient and graft survival with CellCept-based treatment regimens. The studies found significant improvements in liver and kidney transplant outcomes, reducing infectious deaths and increasing graft survival rates.
New guidelines suggest FUZEON is an important treatment for HIV drug resistance, offering clear advice on timing of initiation and patient support. The guidelines aim to enable more pre-treated patients to benefit from FUZEON therapy.
New studies release at the American Urological Association (AUA) show Enablex significantly reducing overactive bladder symptoms, including incontinence episodes and nocturia. Enablex improved efficacy parameters associated with OAB without CNS or CV safety concerns.
ACTOS, an insulin sensitizer, is shown to improve diabetic dyslipidemia components when administered in combination with other diabetes therapies. The study found significant increases in average and peak LDL and HDL particle size, accompanied by a decrease in particle density.
The study found that CellCept significantly reduced the risk of malignancy in patients following heart transplantation, with a 27% lower relative risk compared to azathioprine (AZA). The use of CellCept was also associated with a reduced risk of certain rare cancers, particularly skin cancer.
A new study further reinforces CellCept's cardioprotective profile, demonstrating lower rates of coronary artery disease in patients treated with CellCept compared to azathioprine. This finding could explain the superior survival benefits observed with CellCept.
AstraZeneca has submitted a regulatory application to the European Union for the use of Atacand in treating heart failure. The CHARM study programme showed that Atacand reduces both cardiovascular deaths and hospital admissions across a broad spectrum of patients with chronic heart failure.
Rimonabant demonstrated significant weight loss and improvement in metabolic profile in patients with obesity and untreated dyslipidemia. The drug also improved cardiovascular risk factors, including HDL-cholesterol and triglycerides, by reducing inflammation and increasing adiponectin levels.
Rimonabant successfully treated tobacco dependence and reduced post-cessation weight gain in a double-blind trial. Patients who received the 20mg dose had higher abstinence rates and less weight gain compared to those on placebo.
A new analysis found that Atacand(R) improved NYHA functional class in a broad spectrum of CHF patients, with 35.4% showing improvement and 9% worsening. The medication also reduced the development of atrial fibrillation and Type II diabetes mellitus in these patients.
A new analysis of FUZEON data found that it does not increase lipodystrophy or glucose levels in pre-treated HIV patients. The treatment also showed a lower incidence of diarrhoea compared to other ARV regimens.
The Roche Organ Transplantation Research Foundation has awarded 11 new grants totaling 2 million Swiss francs, focusing on the understanding of rejection responses and inflammation. The grants aim to improve long-term organ survival and help more people with solid organ transplants live longer and healthier lives.
A new survey reveals that people with psoriasis experience severe effects on self-confidence, work, and social life. The study found that three-quarters of those with severe psoriasis reported low self-confidence, while 48% of those with moderate psoriasis also suffered from it.
The SCOPE study found a significant 42% relative risk reduction in fatal/non-fatal strokes in the Atacand group compared to the control group. The study showed that Atacand offers important clinical benefits by reducing the risk of stroke in elderly patients with isolated systolic hypertension.
The European Parliament calls on Eastern European countries to share knowledge and resources to combat HIV resistance. FUZEON, a new treatment, has been shown to reduce HIV levels and increase CD4 cell counts in patients with drug-resistant strains.